Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Clinical trial NCT06759181 · RECRUITING
Trial details
- NCT number
- NCT06759181
- Sponsor
- Xuzhou Medical University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-31
- Primary completion
- 2027-12-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.